Early results of $sup 125$I therapy of thyrotoxic Graves' disease

Journal Article · Mon Apr 01 04:00:00 EDT 1974 · J. Nucl. Med., v. 15, no. 4, pp. 257-260

OSTI ID:4331393

Siemsen, J K; Wallack, M S; Martin, R B; Nicoloff, J T

In an attempt to reduce the high incidence of hypothyroidism following radioiodine treatment of Graves' disease, /sup 125/I was used instead of /sup 131/ I. The low-energy emissions of /sup 125/I theoretically deliver less radiation to the nucleus of the thyroid cell than to its hormone-generating apex. Sixty patients were treated with an estimated delivered high dose of 200 mu Ci/gm and forty with a low dose of 100 mu Ci/gm. After more than 12 months followup, 71% of the high-dose group were euthyroid, 24% still hyperthyroid but half of these substantially improved, and 5% hypothyroid. The low-dose treatment was a failure since 53% of the patients remained toxic. It is concluded that /sup 125/I in the dose range of 200 mu Ci/gm is effective in controlling Graves' disease. Subsequent followup will reveal whether its use will reduce the incidence of late hypothyroidism. (auth)

• Research Organization: Univ. of Southern California, Los Angeles
• NSA Number: NSA-29-029843
• OSTI ID: 4331393
• Journal Information: J. Nucl. Med., v. 15, no. 4, pp. 257-260, Journal Name: J. Nucl. Med., v. 15, no. 4, pp. 257-260; ISSN JNMEA
• Country of Publication: Country unknown/Code not available
• Language: English

Related Subjects

HYPERTHYROIDISM
IODINE 125
N48610* --Life Sciences--Radionuclide Effects (Internal Source)--Man
PATIENTS RADIOINDUCTION